The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Lyme Disease Vaccine Market During The Forecast Period 2026–2030?
The lyme disease vaccine market has demonstrated strong growth in recent years. This market is projected to expand from $1.12 billion in 2025 to $1.2 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. The historical expansion can be attributed to factors such as the increasing occurrence of lyme disease in endemic regions, past limitations of antibiotic-only treatment methods, early initiatives in vaccine research, a growing understanding of tick-borne infections, and improvements in public health surveillance.
The lyme disease vaccine market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $1.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth during the forecast period is fueled by several factors, including the broadening of vaccination initiatives in regions where the disease is prevalent, a surge in funding for infectious disease prevention, the evolution of advanced vaccine platforms, the increasing use of combination vaccines, and an intensified worldwide emphasis on controlling zoonotic diseases. Key trends anticipated over this period encompass improvements in recombinant vaccine technologies, a heightened dedication to preventive immunization strategies, an expansion of clinical investigations into tick-borne illnesses, a greater focus on developing solutions for sustained immunity, and an increase in partnerships between public and private healthcare entities.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp
Which Major Factors Are Driving The Expansion Of The Lyme Disease Vaccine Market?
The rising occurrence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market in the future. Lyme disease, an infection transmitted by ticks caused by Borrelia bacteria, manifests as fever, tiredness, skin rash, and potentially severe joint, cardiac, or neurological issues if left untreated. This rise in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend the areas where ticks can live, leading to more human contact with infected ticks. Lyme disease vaccines contribute to prevention by educating the immune system to identify and combat Borrelia bacteria, thereby lowering infection risks. They streamline disease management through sustained protection, which enhances overall public health. For example, in March 2025, the Centers for Disease Control and Prevention, a US-based federal health agency, reported about 89,000 cases of Lyme disease in the United States in 2023, while alternative estimation methods suggest that around 476,000 people might be diagnosed and treated for Lyme disease annually. Consequently, the growing prevalence of Lyme disease is a key factor propelling the growth of the Lyme disease vaccine market. The increasing outlay on healthcare is also projected to stimulate the expansion of the Lyme disease vaccine market. Healthcare expenditure encompasses the total financial investment in medical services, treatments, facilities, research endeavors, and public health programs aimed at maintaining or improving population health. The heightened need for healthcare spending stems from the growing incidence of chronic conditions that demand extended and expensive care. Elevated healthcare expenditure facilitates the progress of Lyme disease vaccine development by ensuring greater financial support for research and clinical trials, thus speeding up innovation and manufacturing. It also backs advanced vaccine technologies, thereby improving their availability and efficacy for populations at risk. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, representing a 0.9% growth compared to 2022. Consequently, the upward trend in healthcare spending is a significant factor propelling the growth of the Lyme disease vaccine market.
What Market Segments Are Evaluated Within The Lyme Disease Vaccine Market?
The lyme disease vaccine market covered in this report is segmented –
1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types
2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels
5) By End User: Hospitals, Clinical Laboratories, Other End Users
Subsegments:
1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines
2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines
3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines
4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines
What Industry Trends Are Redefining The Lyme Disease Vaccine Market?
Leading companies active in the Lyme disease vaccine market are concentrating on advancing their product candidates in late-age development, such as booster vaccines, to address unmet medical requirements, improve immune defense, and simplify vaccination protocols. Booster vaccines represent additional doses administered after the initial immunization to re-establish or enhance long-term immunity. For instance, in September 2025, Valneva SE, a France-based biotechnology company, affirmed positive immunogenicity and safety findings from the ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This vaccine is multivalent, designed to train the immune system to produce antibodies against OspA proteins located on Borrelia bacteria. When a tick bites, these antibodies impede the bacteria inside the tick, thereby preventing human infection. The strong immune response and favorable safety profile observed after a third booster dose were in line with those reported after receiving prior annual booster doses, further indicating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is intended to provide ongoing protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for individuals facing risk.
Who Are The Top Market Participants Influencing The Lyme Disease Vaccine Market?
Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.
Read the full lyme disease vaccine market report here:
https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report
Which Region Currently Holds The Largest Share Of The Lyme Disease Vaccine Market?
North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Lyme Disease Vaccine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30317&type=smp
Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Dog Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model